Using Foreign Clinical Studies for EAEU Registration: When a GCP Inspection Can Replace a New Local Trial

A foreign clinical-development programme does not automatically have to be repeated in Russia or another Eurasian Economic Union country before a medicinal product can be registered under EAEU rules.

For studies initiated after 1 January 2016, however, EEC Council Decision No. 78 contains a specific territorial and compliance framework. Where the ordinary conditions for accepting the clinical programme are not met—for example because all relevant pivotal studies were conducted entirely outside the EAEU—the applicant can face a strategic choice:

conduct at least one clinical study wholly or partly in the EAEU before filing, or proceed with the foreign evidence package and allow the reference-state authority to appoint an unscheduled GCP inspection of a clinical site during the registration procedure.

This second pathway is often overlooked by international regulatory teams.

It can preserve an otherwise adequate global clinical programme and avoid repeating a scientifically unnecessary local trial. But it transfers part of the regulatory risk from generating new data to proving the reliability, GCP compliance and inspectability of the existing data.

The correct question is therefore not:

“Do we have a Russian clinical trial?”

It is:

“Does our foreign clinical evidence fit the EAEU acceptance conditions, and if not, is the dossier and study infrastructure strong enough to support a GCP-inspection pathway?”

Decision No. 78 contains a specific route for third-country clinical data

Paragraph 36 of Decision No. 78 sets the core rules for clinical-study reports included in Module 5.

The Rules distinguish among several historical and procedural situations.

Clinical studies may be considered where, among other conditions:

• they were conducted under member-state legislation on EAEU territory before the applicable 2016 transition cut-off;
• they were conducted partly or wholly in ICH-region countries before 1 January 2016 and supported registration in the ICH region;
• for studies initiated after 1 January 2016, they were conducted in accordance with the applicable EAEU legal framework and at least one clinical study was conducted wholly or partly, with patient data obtained, on EAEU territory.

If those ordinary conditions are not satisfied, paragraph 36 gives two routes:

1. before filing, the applicant conducts at least one clinical study wholly or partly in the EAEU, with the study selected by the applicant and agreed with the competent authority; or
2. during registration, the competent authority decides to appoint an unscheduled pharmaceutical inspection of one of the clinical sites where the submitted clinical study was conducted.

Paragraph 36 does not apply to orphan medicinal products.

This is the legal foundation for the “foreign clinical programme + GCP inspection” pathway.

NCESMP now describes this pathway explicitly

The Russian reference-state expert institution, FGBU NCESMP, updated its public pharmaceutical-inspection guidance in 2026.

Its current guidance states directly that where a dossier contains no local clinical study conducted in an EAEU member state, the applicant may include reports of studies conducted entirely in third countries, but in that case a pharmaceutical inspection of the clinical study is appointed under paragraph 36 of Decision No. 78.

NCESMP also publishes the status and outcomes of GLP/GCP inspections performed during registration procedures.

The 2025 and 2026 public lists include actual unscheduled clinical-study inspections performed during EAEU mutual-recognition procedures, including studies of biological/biosimilar medicinal products.

At RegLek-2026, NCESMP dedicated a separate session to GLP/GCP pharmaceutical inspections during medicinal-product registration and to practical preparation for those inspections. This confirms that the inspection pathway is not theoretical—it is an active part of Russian EAEU registration practice in 2026.

Inspection is not merely a substitute “certificate” for a local study

The purpose of GCP inspection is not to create local clinical data.

It is to determine whether the foreign study data relied on in the registration dossier are credible, complete and generated in accordance with acceptable Good Clinical Practice, including protection of trial participants and integrity of the data.

The inspection can examine:

• trial authorization and ethics approval;
• informed consent;
• protocol compliance;
• source data and case-report forms;
• investigator responsibilities;
• investigational-product accountability;
• randomization/blinding controls;
• safety reporting;
• laboratory and diagnostic procedures;
• monitoring;
• data management;
• statistical-data traceability;
• sponsor oversight;
• CRO activities;
• essential documents and archiving;
• computerized systems used to generate or store trial data.

A successful inspection supports the regulatory usability of the submitted clinical evidence. It does not change the scientific design of the study after the fact.

A study that is GCP-compliant but scientifically incapable of supporting the claimed indication can still be insufficient for registration.

Paragraph 37 creates a broader risk-based inspection mechanism

Even where paragraph 36 is satisfied, Decision No. 78 gives the reference-state authority a risk-based power to inspect clinical studies, including bioequivalence studies.

Under paragraph 37, the authority can:

• appoint an unscheduled inspection during the registration procedure; or
• include the study in the planned inspection programme during the first three years after registration.

A planned post-registration inspection is performed in at least one clinical site under the EAEU pharmaceutical-inspection rules.

This means participation of an EAEU site does not make the rest of a global programme immune from inspection.

The inspection decision remains risk-based.

What can trigger an unscheduled GCP inspection

Paragraph 38 of Decision No. 78 lists risk factors that can support an inspection decision.

They include issues such as:

• missing or unclear ethics-committee approval;
• concerns regarding informed consent or participant information;
• unclear administrative structure of the trial;
• substantial amendments not properly reflected in the protocol or study documentation;
• insufficient description of efficacy or safety endpoint methods;
• unjustified exclusion of subjects from statistical analyses;
• inconsistencies between protocol and clinical study report;
• incomplete, contradictory or implausible data;
• excessive missing data capable of affecting statistical power;
• other circumstances that put the reliability of the study results in doubt.

For bioequivalence studies, Decision No. 78 contains an additional risk-based assessment under paragraph 39.

The practical implication is important:

an inspection can be triggered either because the programme relies entirely on third-country data or because the dossier itself creates a credibility signal.

Those are different risk pathways and should be managed differently.

Before filing, perform a “GCP inspectability” assessment—not only a CSR review

A registration team often reviews the clinical study report and concludes that the efficacy/safety data are strong.

That is necessary but not sufficient for an inspection pathway.

The question is whether the underlying trial can still be inspected years later.

Pharegis assesses:

• whether the selected clinical sites still operate;
• whether investigators and key staff can be identified;
• whether essential documents remain archived and accessible;
• whether source records can be retrieved;
• whether electronic systems and audit trails remain accessible;
• whether sponsor and CRO responsibilities are reconstructable;
• whether laboratories or imaging/diagnostic providers used in the trial can support traceability;
• whether the study was previously inspected by an ICH-region regulator;
• whether those inspection reports can be identified and, where permitted, made available to the EAEU authority;
• whether there are unresolved serious GCP findings or data-integrity issues.

A ten-year-old foreign clinical study can be scientifically excellent yet operationally difficult to inspect.

That distinction should be discovered before the registration dossier is filed.

Module 1 already asks for foreign GCP-inspection history

The EAEU dossier requirements themselves reflect this concern.

For a clinical study conducted entirely at sites in third countries, Module 1 requires information on GCP inspections performed at the sites that enrolled the largest numbers of patients, together with information about other inspections at those sites where relevant.

Where the applicable reports are not already included, the competent/expert authority may request inspection information from the corresponding third-country regulators.

This means previous FDA, EMA/member-state, MHRA or other credible regulatory inspection history can be relevant evidence.

But it is not an automatic waiver of the EAEU authority’s right to inspect.

The best use of prior inspection history is as part of a transparent risk profile.

The regulator selects the study and the inspectable subjects

The applicant should not assume it can choose the easiest clinical site.

NCESMP’s current 2026 guidance describes a risk-based selection process.

For a clinical inspection, the expert organization first identifies the clinical study to be inspected from the studies in the registration dossier. It then reviews the organizations involved in that study and determines which subjects should be inspected.

Factors used in selecting clinical sites can include:

• number of patients enrolled at the site;
• rate/dynamics of recruitment;
• participant withdrawals;
• adverse-event patterns by site;
• involvement of external organizations in trial-specific diagnostic or therapeutic procedures;
• other risk signals identified during dossier assessment.

Under Decision No. 83, inspectable subjects can include the clinical site, sponsor, CRO and other organizations involved in the conduct or coordination of the study.

The preparation therefore has to cover the whole evidence chain, not only the principal investigator’s binder.

Site inspection, sponsor/CRO inspection and documentary inspection can coexist

The current EAEU GCP-inspection framework permits several inspection forms and subjects.

Depending on the study structure and risk assessment, the authority can inspect:

• one or more clinical sites;
• sponsor systems;
• CRO systems;
• other organizations involved in the study;
• documents and systems through documentary inspection;
• combinations of on-site and documentary work within the same inspection programme.

NCESMP’s current guidance specifically notes that a single inspection decision can include subjects for both on-site and documentary inspection.

This matters for outsourced global trials.

A study may have been conducted at a strong hospital site but still contain a risk concentrated in central data management, central imaging, pharmacovigilance, randomization or CRO oversight.

The appointment itself creates a regulatory clock

When the Russian authority appoints an unscheduled pharmaceutical inspection, the decision is communicated to the applicant through the expert request/registration system.

NCESMP currently requires the applicant to submit an inspection application within 15 working days from receipt of the decision/request.

The inspection application includes information on the inspectable subject, sponsor and contacts and is accompanied by the documents required to conclude the inspection agreement.

For sites outside the EAEU, the applicant also has to support practical access, including invitation/visa arrangements where required.

This is an operational deadline that global headquarters can miss because the inspection is being managed as an “expert query” rather than as a separate regulated workstream.

Pharegis places the inspection response on the registration critical path immediately when the inspection decision appears.

What happens to the registration expertise while inspection is organized

The current Russian expert guidance makes an important distinction.

The registration expertise is suspended until the applicant submits the required application for the inspection after receiving the inspection decision.

Once the inspection process is underway, NCESMP states that the dossier expertise itself is not suspended for the duration of the unscheduled pharmaceutical inspection.

That means the clinical inspection and other parts of the registration assessment can proceed in parallel.

The project therefore needs two synchronized workstreams:

registration deficiency management

and

GCP inspection preparation/execution.

A regulatory team that waits for one to finish before managing the other can lose time unnecessarily.

Prepare the study like an evidence-reconstruction project

An EAEU GCP inspection can occur years after the study closed.

The preparation should therefore start with a trial reconstruction map.

Pharegis typically maps:

protocol → amendments → site selection → ethics → consent → enrollment → investigational product → efficacy/safety assessments → source data → CRF/EDC → monitoring → queries → database lock → analysis → CSR → Module 5.

For every major endpoint and safety conclusion, the inspection team should be able to trace the result backwards to the underlying controlled records.

The objective is not to create documents that did not exist during the trial.

It is to demonstrate transparently how the trial was actually conducted and how the dossier data were generated.

Language can become a serious inspection risk

A third-country study may have source records, contracts, SOPs and site documentation in Chinese, Korean, Spanish, Portuguese or another language.

The EAEU inspector needs meaningful access to those records.

Translation planning should therefore identify in advance:

• protocol and amendments;
• investigator brochure versions;
• informed consent forms;
• ethics approvals;
• source-record categories;
• CRF/EDC documentation;
• monitoring reports;
• major deviations;
• SAE documentation;
• IMP accountability;
• laboratory and diagnostic documentation;
• data-management/statistical documentation;
• CAPA and audit records.

Not every archived page must be translated pre-emptively, but the sponsor should know how requested evidence will be made understandable without delaying or distorting the inspection.

A prior FDA/EMA inspection helps, but it does not close the EAEU question

Decision No. 78 specifically requires information on previous GCP inspections for third-country sites in relevant dossiers.

A clean previous inspection by an ICH-region regulator can reduce uncertainty around a site or sponsor system.

However, the EAEU authority may be assessing a different study, different endpoint, different period or different risk signal.

A historical inspection report should therefore be used as supporting context, together with:

• scope of the prior inspection;
• date;
• study/site inspected;
• findings;
• CAPA and closure status;
• whether the systems relevant to the EAEU-submitted study were actually inspected.

“FDA inspected this CRO once” is not a regulatory argument.

What inspectors can review during the visit

Decision No. 83 gives inspectors broad access to documents, infrastructure, records, agreements, systems and other sources considered relevant to the clinical study.

NCESMP’s current operational guidance states that assessment is performed through documentation review, inspection of facilities and interviews.

The inspected subject must provide direct and complete access to relevant objects, documentation, records and systems. Refusal of access can itself be documented as an inspection observation.

In practice, readiness should include:

• investigator and study-team interviews;
• patient/source-data tracing;
• consent verification;
• EDC/source reconciliation;
• endpoint verification;
• investigational-product accountability;
• safety-event tracing;
• protocol-deviation review;
• monitoring/audit follow-up;
• sponsor/CRO oversight;
• electronic-system audit trails where applicable.

The inspection tests whether the study remains defensible when the regulator leaves the CSR and follows the raw evidence.

Findings are classified by their effect on rights and data credibility

Current Decision No. 83 classifies GCP inspection findings by severity.

Critical findings are those capable of materially affecting data quality, integrity or reliability or adversely affecting trial-participant rights, safety or well-being.

Other findings are classified according to the current inspection rules and their regulatory significance.

The inspection report does more than list procedural deviations. NCESMP states that it concludes whether the quality of the inspected data allows those data to be used in assessment of the registration application, and can identify which part of a study should be regarded as unreliable.

This is the central commercial risk of the pathway:

a failed inspection can remove the evidence on which the benefit-risk conclusion depends.

The CAPA response is part of the registration outcome

After receipt of the inspection report, the inspected subject has a current NCESMP response window of 20 working days to provide its response to the report.

The response should not merely dispute wording.

For each significant finding it should address:

finding → immediate correction/containment → root cause → scope/extent → impact on participant rights or data → corrective action → preventive action → evidence → effectiveness check.

Where the issue affects the reliability of a subset of patients or a specific endpoint, the sponsor may also need a scientific/statistical impact analysis.

NCESMP’s current guidance states that critical findings, or an unsatisfactory evaluation of the CAPA plan and implementation report, can prevent a positive registration/renewal/variation decision. Significant findings can require verification of remediation, including repeat inspection where applicable.

A CAPA strategy is therefore a regulatory submission, not merely a quality-system response.

The foreign-data pathway can be better than repeating a local trial—but only when the study is inspectable

The pathway is particularly attractive where:

• the existing pivotal programme is scientifically adequate for the proposed EAEU indication;
• the studies were performed to strong international GCP standards;
• sponsor/CRO/site documentation remains accessible;
• source data and essential documents can still be inspected;
• the study population and endpoints are relevant to the EAEU benefit-risk assessment;
• the cost and ethics of repeating a local study are difficult to justify.

It is less attractive where:

• the trial sites have closed or archives are uncertain;
• sponsor/CRO ownership has changed and systems cannot be reconstructed;
• there were unresolved data-integrity concerns;
• major protocol/CSR inconsistencies exist;
• the pivotal evidence itself is scientifically weak;
• the manufacturer cannot provide regulatory access to third-country sites or systems.

In those cases, a new EAEU study may be the more controllable route.

Bioequivalence studies can also be inspected

Decision No. 78 expressly includes bioequivalence studies within the risk-based GCP-inspection framework.

For BE studies, inspection risk extends beyond the clinical unit.

Depending on the concern, the inspection can examine:

• subject enrollment and dosing;
• randomization;
• sample collection and handling;
• chain of custody;
• bioanalytical laboratory processes;
• chromatographic data;
• repeat analysis;
• incurred-sample reanalysis;
• PK/statistical data flows;
• CRO/sponsor oversight.

A foreign BE study should therefore be assessed for inspectability of both the clinical and bioanalytical evidence chain before it is relied on for EAEU registration.

The 2024–2025 inspection-rule updates make risk-based preparation more important

Decision No. 83 has been materially updated, including amendments adopted in 2024 and 2025.

The current GCP-inspection framework recognizes on-site, remote and documentary inspection tools and formally incorporates risk-oriented planning and selection of inspected subjects.

For the applicant, this does not reduce the need for readiness.

It increases the need to understand where the regulatory risk actually sits: one high-enrolling site, the CRO, a central laboratory, the sponsor’s data-management system, or the relationship among them.

The inspection preparation plan should follow that risk architecture.

What Pharegis manages in a foreign-clinical-data / GCP-inspection project

Pharegis can assess the pathway before filing or take over an inspection workstream after an inspection decision is issued.

Typical deliverables include:

• paragraph 36 pathway memo: local EAEU study vs foreign-data/GCP-inspection route;
• Module 5 regulatory-usability assessment;
• review of previous third-country GCP inspection history;
• GCP inspectability gap assessment for sponsor, CRO and clinical sites;
• identification of high-risk / high-enrollment sites likely to attract inspection attention;
• protocol-to-CSR consistency review;
• source-data and endpoint traceability map;
• essential-document/archiving gap review;
• sponsor/CRO responsibility matrix;
• preparation of the Russian inspection application and administrative package;
• coordination with NCESMP and the applicant’s global clinical organization;
• translation and interpreter planning;
• inspection-room / document-request process;
• mock interviews and evidence-retrieval testing;
• regulatory support during inspection;
• inspection-report and data-impact assessment;
• CAPA strategy and response review;
• assessment of whether findings affect Module 5, benefit-risk conclusions or product information.

For a manufacturer without a regional clinical-regulatory team, Pharegis can serve as the local interface between NCESMP inspectors and the global sponsor/CRO/site network.

Discuss whether foreign trials can support EAEU registration without a new local trial

For an initial assessment, prepare:

• product and proposed EAEU application type;
• list of pivotal and supportive clinical studies;
• study initiation and completion dates;
• countries and sites involved;
• patient enrollment by site;
• whether any EAEU site participated;
• study reports and protocols;
• ethics/GCP documentation;
• previous regulatory inspections of sponsor, CRO and sites;
• current archive/location of source and essential documents;
• major audit findings, CAPA or known data-integrity issues;
• intended EAEU reference state and filing date.

Pharegis can then determine whether the clinical programme satisfies the ordinary Decision No. 78 conditions, whether the paragraph 36 inspection route is realistic, and what has to be repaired before the dossier is exposed to regulatory inspection.

The objective is not to avoid EAEU clinical requirements. It is to use the existing global evidence when it is scientifically adequate—and prove, through an inspectable evidence chain, that the EAEU authority can rely on it.

Regulatory and current-practice basis

• EEC Council Decision No. 78 of 3 November 2016 — paragraphs 35–39 on acceptance and inspection of nonclinical/clinical evidence, including the paragraph 36 pathway for third-country studies.
• EEC Council Decision No. 83 of 3 November 2016 — Rules for Pharmaceutical Inspections, including current GCP-inspection provisions as amended.
• EEC Council Decision No. 66 of 6 September 2024 — major update of the GCP pharmaceutical-inspection framework under Decision No. 83.
• EEC Council Decision No. 79 of 3 November 2016 — EAEU Good Clinical Practice Rules, including the 2025 amendments.
• FGBU NCESMP, “General Information on Pharmaceutical Inspections,” current 2026 guidance on appointment, risk-based site/subject selection, inspection preparation and outcomes.
• FGBU NCESMP public register of clinical-study pharmaceutical inspections, including 2025–2026 unscheduled inspections performed during EAEU registration procedures.
• RegLek-2026 — current Russian expert-practice discussions on GLP/GCP inspections during medicinal-product registration and inspection readiness.

Regulatory status reviewed: August 2026.